课题基金 / 基金详情

Natural Product-Drug Interaction Research: The Roadmap to Best Practices

Natural Product-Drug Interaction Research: The Roadmap to Best Practices
天然产物-药物相互作用研究:最佳实践路线图
批准号:
10704756
负责人:
MARY F PAINE
金额:
$213.62万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
未结题
起止时间:
2015-09-01 至 2025-08-31

项目摘要

项目成果

MARY F PAINE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY OF THE OVERALL U54 CENTER Assessing the risk of adverse natural product (NP)-drug interactions (NPDIs) is of paramount importance due to the exponential NP sales growth in the US. This effort is challenged by relatively scant pharmacokinetic knowledge of individual NP constituents that precipitate these interactions and a lack of mechanistic understanding of NP effects on drug disposition. Investigations of NPDIs to address these knowledge gaps are complicated by the inherently large variability in phytoconstituent composition of supposedly the same NP, acquisition of sufficient high-quality NP study materials, and the diverse populations to which NPs are marketed, including the elderly. Our established Center of Excellence for Natural Product Drug Interaction Research (NaPDI Center) was created by the National Center for Complementary and Integrative Heath (NCCIH) in 2015 to address this public health problem. A cross-disciplinary research team composed of experts in clinical pharmacology, NP chemistry, biomedical informatics, and health communications led the charge to address the challenges unique to NPDI research. As detailed in this renewal application, we will advance the mission of the NaPDI Center by designing and executing new mechanistically-driven Interaction Projects, expanding the utility of our web-based data repository and public portal, and broadening dissemination of knowledge to national and international research communities. These activities will be accomplished through synergistic interactions between three established scientific Cores (Pharmacology, Analytical, and Informatics) and an overarching Administrative Core. The Pharmacology Core will expand an innovative method to select three to five high priority NPs to study as precipitants of potential clinically significant NPDIs. The Analytical Core will source and fully characterize the chemical composition of commercially available, representative NPs and provide NP study materials free of adulterants and contaminants for the Interaction Projects. The Pharmacology Core will design and execute rigorous in vitro studies to establish the mechanism of NP effects on drug disposition; predict the magnitude of NPDIs using physiologically-based pharmacokinetic modeling and simulation; and design and conduct clinical NPDI studies. The Analytical Core will provide quantitative analysis of object drugs, NP constituents, and emerging drug disposition biomarkers in the human pharmacokinetic samples. The interpreted data generated from the Interaction Projects will be transferred to the data repository developed and maintained by the Informatics Core. Major findings will be disseminated to scientific and other interested communities through our unique public access web portal perpetuated by the Informatics Core. All Cores will share the task of broadening Center outreach activities through targeted workshops and symposia at national and international scientific meetings. A Steering Committee composed of Core leaders and NCCIH officials will jointly oversee Center scientific progress with an External Advisory Panel of experts in relevant fields selected by NCCIH.
期刊论文(53)
专著(0)
科研奖励(0)
会议论文
Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
健康成人参与者中细胞色素 P450 介导的大麻素-药物相互作用的评估。
DOI: 10.1002/cpt.2973
发表时间: 2023
期刊: Clinical pharmacology and therapeutics
影响因子: 6.7
作者: [Bansal,Sumit, Zamarripa,CAustin, Spindle,ToryR, Weerts,EliseM, Thummel,KennethE, Vandrey,Ryan, Paine,MaryF, Unadkat,JashvantD]
通讯作者: Unadkat,JashvantD
DOI: 10.1038/s41598-020-76119-w
发表时间: 2020-11-05
期刊: Scientific reports
影响因子: 4.6
作者: [Todd DA, Kellogg JJ, Wallace ED, Khin M, Flores-Bocanegra L, Tanna RS, McIntosh S, Raja HA, Graf TN, Hemby SE, Paine MF, Oberlies NH, Cech NB]
通讯作者: Cech NB
DOI: 10.1002/cpt.2670
发表时间: 2022-09
期刊: CLINICAL PHARMACOLOGY & THERAPEUTICS
影响因子: 6.7
作者: [Taskar, Kunal S., Yang, Xinning, Neuhoff, Sibylle, Patel, Mitesh, Yoshida, Kenta, Paine, Mary F., Brouwer, Kim L. R., Chu, Xiaoyan, Sugiyama, Yuichi, Cook, Jack, Polli, Joseph W., Hanna, Imad, Lai, Yurong, Zamek-Gliszczynski, Maciej]
通讯作者: Zamek-Gliszczynski, Maciej
DOI: 10.1111/cts.13505
发表时间: 2023-06
期刊: Clinical and translational science
影响因子: --
作者: []
通讯作者:
29
    Administrative Core
    • 批准号:
      10254442
    • 项目类别:
    • 资助金额:
      $31.73万
    • 财政年份:
      2015
    • 负责人:
      MARY F PAINE
    • 依托单位:
    Pharmacology Core
    • 批准号:
      10254443
    • 项目类别:
    • 资助金额:
      $68.86万
    • 财政年份:
      2015
    • 负责人:
      MARY F PAINE
    • 依托单位:
    Natural Product-Drug Interaction Research: The Roadmap to Best Practices
    • 批准号:
      10471289
    • 项目类别:
    • 资助金额:
      $217.64万
    • 财政年份:
      2015
    • 负责人:
      MARY F PAINE
    • 依托单位:
    Administrative Core
    • 批准号:
      10062144
    • 项目类别:
    • 资助金额:
      $31.73万
    • 财政年份:
      2015
    • 负责人:
      MARY F PAINE
    • 依托单位:
    海外基金